Decoding Cancer: How Advanced Tumor Profiling is Revolutionizing Treatment
"A deep dive into TumorNext, a comprehensive approach combining NGS and OncoScan for personalized cancer therapy."
The landscape of cancer treatment is rapidly evolving, driven by the development of targeted therapies that address both germline and somatic DNA mutations. This progress has created a critical need for sophisticated molecular profiling assays capable of precisely determining the mutational status of specific genes. The potential benefits of prescribing targeted therapies based on a tumor’s unique DNA alterations, rather than traditional tissue pathology, are becoming increasingly clear.
Traditional methods for characterizing tumors, such as immunohistochemistry (IHC) and in situ hybridization (ISH), are highly specific but provide limited information. Next-generation sequencing (NGS) offers an unbiased approach, providing extensive genomic data. However, the high costs and complex bioinformatics associated with whole genome sequencing (WGS) make it prohibitive for routine clinical use. Targeted gene panels are emerging as the optimal solution, balancing comprehensive analysis with cost-effectiveness.
This article explores TumorNext, a custom probe-based NGS tumor panel designed to detect single nucleotide variants, small insertions and deletions in 142 genes frequently mutated in somatic and germline cancers. TumorNext also identifies gene fusions and structural variants in 15 frequently disrupted oncogenes and tumor suppressors. Paired with a matched control and a custom bioinformatics pipeline, TumorNext distinguishes between somatic and germline mutations, enabling precise variant classification.
A Market on a Growth Trajectory
Tumor profiling starts with a tissue sample, usually taken by core biopsy or during surgery, from which tumor DNA is extracted, purified, and sent to a lab for analysis. Data Bridge Market Research reports that the global cancer tumor profiling market was valued at USD 9,543.13 million in 2022 and is projected to reach USD 26,840.23 million by 2030, a compound annual growth rate of 12.5%. The field is broad: the market is segmented by technique (genomics, proteomics, epigenetics, and metabolomics) and by technology (sequencing, quantitative PCR, immunohistochemistry, in situ hybridization, and microarray). Market intelligence platforms have also emerged to give strategy teams and analysts instant access to cancer tumor profiling market datasets.
Comprehensive Profiling, Uncertain Interpretation
Standard tumor profiling extracts and analyzes DNA from tissue obtained by core biopsy or during surgery, but the field now reaches well beyond basic sequencing. The University of Zurich's 'Tumor Profiler' project, for example, aims to derive comprehensive molecular profiles of tumors that could predict the efficacy of a host of new cancer medications. The diversity of clinical profiling approaches—from small gene panels to whole exomes, with matched or unmatched germline analysis—may engender uncertainty in interpretation, a notable limitation of current practice. Recent work shows that running nine molecular methods in parallel can deliver single-cell-level tumor analysis within four weeks, yielding individualized treatment recommendations for complex cancers. Tumor context also matters: highly infiltrated 'hot' tumors respond far better to immune checkpoint inhibitors than 'cold' tumors with scarce immune infiltration.
From Grim Diagnoses to Molecular Milestones
For much of modern medical history, a diagnosis of cancer was often viewed as an immediate, life-threatening event, with little appreciation of what made each tumor different. The concept of using the immune system to fight cancer traces back to the late 19th century, laying early conceptual groundwork for today's immunotherapies. A more recent milestone is the Tumor Profiler Study, an observational trial combining a prospective diagnostic approach—assessing the relevance of in-depth tumor profiling for clinical decision-making—with an exploratory approach to improve biological understanding of the disease. The field continues to evolve with digital pathology and spatial tumor profiling, which computationally examine the tumor microenvironment. Even surprising findings, such as a bacterium from Japanese tree frogs that reportedly erased tumors in mice with a single dose, hint at novel directions for cancer therapy.
The Power of Combined NGS and OncoScan
TumorNext’s comprehensive approach combines NGS with OncoScan, an array technology for high-resolution copy number variant detection. This combination allows for the detection of single copy amplifications and hemizygous deletions, offering a complete genomic profile of the tumor. By analyzing both SNVs, indels, SVs, and CNVs, TumorNext provides a multi-faceted view of the tumor's genetic makeup.
- Enhanced Accuracy: Reduces the risk of misclassifying variants, leading to more appropriate treatment decisions.
- Comprehensive Profiling: Provides a complete genomic picture of the tumor, including SNVs, indels, SVs, and CNVs.
- Personalized Treatment: Enables the selection of targeted therapies based on the tumor’s unique genetic alterations.
- Improved Outcomes: By identifying the "second hit" in hereditary cancer patients, TumorNext can guide more effective treatment strategies.
Reading Every Tumor's Signature
A study by the Tumor Profiler Center (University Hospital Zurich, University of Zurich, ETH Zurich, and University Hospital Basel) used nine different molecular methods to analyze tumors, offering hope for more precise skin cancer care in recognition that every tumor is unique. In lung cancer, researchers describe an era of extraordinary advances in profiling tumor complexity, with metabolomic profiling helping unravel tumor heterogeneity even as the arsenal of targeted therapies grows. A wide-ranging analysis of more than 5,500 breast cancer tumors that combined genomic and protein expression testing has also identified promising targets for patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Promise vs. Proof in the Clinic
Researchers have been clamoring for more tumor profiling since the cancer 'Moonshot' was first announced, and a panel has urged that profiling be included in such plans. Yet immunotherapy—one of the hottest areas of cancer research—is currently successful only in a limited number of patients, a reminder that the promise of molecular analysis has not fully translated into broad clinical wins. Tumor profiling itself involves analyzing the genetic, molecular, and cellular characteristics of cancerous tissues to identify specific biomarkers, mutations, and pathways, and its ultimate value rests on turning those findings into effective, durable treatments for more people.
Weighing Regimens and Profiling Depth
Comparative research in oncology takes many forms, from head-to-head drug schedule trials to evaluations of how much molecular detail is worth gathering. A randomized phase II study, for instance, examined daily versus alternate-day treatment with the oral agent S-1 in gastric cancer, building on earlier cell-line work that compared the two schedules for tumor growth inhibition and toxicity reduction. In the profiling arena, the Tumor Profiler Study is a prospective, observational clinical trial that exploits recent technological advances to profile tumor samples to an unparalleled level with respect to molecular and spatial composition as well as treatment response. Such comparisons help clinicians weigh trade-offs between treatment intensity and tolerability while gauging whether deeper profiling actually improves decision-making.
Looking Ahead
TumorNext represents a significant advancement in cancer diagnostics, offering a comprehensive and accurate method for tumor profiling. By combining NGS and OncoScan, and by differentiating between somatic and germline mutations, TumorNext empowers clinicians to make more informed treatment decisions, ultimately improving patient outcomes. As personalized medicine continues to evolve, TumorNext exemplifies the potential of advanced genomic technologies to revolutionize cancer care.
Clinicians Still Hold the Final Word
In the Tumor Profiler Study, where the tumors of 116 patients were analyzed, the focus fell on how long tumor analysis took to become available and how treating physicians assessed the resulting recommendations—two key factors for successfully applying tumor profiling in practice. Because randomized evidence on overall survival or progression-free survival is not yet available, the initial assessment of clinical utility in such studies rests on the expert opinion of both a pre-Tumor Board and a Tumor Board. Expert judgment also guides small-specimen biomarker testing in non-small cell lung cancer, which weighs alterations such as TP53 and BRCA1/2 as well as emerging predictors of immunotherapy response like tumor mutational burden (TMB) and comprehensive genomic profiling (CGP). Diagnostics providers are responding to this demand by expanding portfolios with hereditary tumor panels, molecular tumor analysis, and liquid biopsy offerings.
Toward Single Cells and Liquid Biopsies
The future outlook for tumor profiling technologies is promising, with innovations like single-cell analysis, liquid biopsies, and AI-driven diagnostics expected to enhance capabilities and accessibility. Regional markets reflect this momentum: specialized research firms actively monitor the India tumor profiling market and publish annual reports covering emerging trends, growth drivers, revenue analysis, and forecast outlook. Together, these developments point toward profiling that is both more powerful and more widely available in the years ahead.
Access, Cost, and the Germline Question
Tumor profiling programs surface challenges that extend well beyond the laboratory. In one program, tumor profiling was offered to 1,960 advanced cancer patients, and 1,556 underwent tumor-normal sequencing with multigene hotspot panels containing 20 cancer predisposition genes—generating additional germline findings that demand careful follow-up and counseling. Access to advanced therapies illustrates broader systemic issues: as cell-based treatments such as CAR T therapy expand beyond major academic institutions, significant challenges remain, tied to insurance hurdles, high costs, and insufficient health policy support. Regional markets, meanwhile, see opportunities in AI integration, broader use of liquid biopsies, growth in companion diagnostics, and strengthened academic–industry partnerships, even as these systemic gaps persist.
When Profiling Changes a Patient's Course
Real-world examples show how tumor profiling shifts cancer care from a one-size-fits-all approach toward precision medicine, allowing doctors to recommend treatments that are more effective, less toxic, and better matched to each patient's cancer. A landmark study published in Nature Medicine by the Tumor Profiler Center demonstrated the feasibility and clinical impact of multi-omics tumor profiling for guiding melanoma treatment. In pediatrics, a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential to impact clinical care, including clarifying diagnoses and enabling treatment with matched, precision cancer drugs.